Jefferies Keeps Buy Rating on ARIAD Pharma (ARIA); Still Positive on Iclusig Amid Ph. 3 Halt
Tweet Send to a Friend
Jefferies maintains a Buy rating and $7 price target on ARIAD Pharmaceuticals (Nasdaq: ARIA) following recent news that it would ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
